In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $9.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors including Rocket Pharmaceuticals’ strategic corporate reorganization and pipeline prioritization. The company is focusing its efforts on its cardiovascular AAV gene therapy franchise, which shows promise in treating various cardiomyopathies. Additionally, Rocket is progressing towards a BLA resubmission for Kresladi, despite delaying other programs.
The restructuring also includes a significant reduction in workforce, which is expected to extend the company’s cash runway into the second quarter of 2027. This financial strategy, coupled with potential revenues from a PRV sale contingent on Kresladi’s approval, strengthens the company’s financial position. Despite challenges such as the clinical hold on RP-A501, the company’s focus on optimizing its immunomodulatory regimen and addressing safety concerns reflects a proactive approach to advancing its pipeline.
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Liquidia Technologies, and Rocket Pharmaceuticals. According to TipRanks, Jubinville, PhD has an average return of 0.2% and a 39.56% success rate on recommended stocks.
In another report released on July 17, Wedbush also maintained a Buy rating on the stock with a $16.00 price target.